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Abstract
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Complications in pregnancy elevate fetal norepinephrine (NE) concentrations. Previous studies in
NE-infused sheep fetuses revealed that sustained exposure to high NE resulted in lower expression
of α2-adrenergic receptors in islets and increased insulin secretion responsiveness after acutely
terminating the NE infusion. In this study, we determined if the compensatory increase in insulin
secretion following chronic elevation of NE is independent of hyperglycemia in sheep fetuses and
whether it is persistent in conjunction with islet desensitization to NE. Following an initial
assessment of glucose-stimulated insulin secretion (GSIS) at 129±1 days of gestation, fetuses were
continuously infused for seven days with NE and maintained at euglycemia with a maternal
insulin infusion. Fetal GSIS studies were again performed on days 8 and 12. Adrenergic sensitivity
was determined in pancreatic islets collected at day 12. NE infusion increased (P<0.01) fetal
plasma NE concentrations and lowered (P<0.01) basal insulin concentrations compared to vehicleinfused controls. GSIS was 1.8-fold greater (P<0.05) in NE-infused fetuses compared to controls
at both one and five days after discontinuing the infusion. Glucose-potentiated arginine-induced
insulin secretion was also enhanced (P<0.01) in NE-infused fetuses. Maximum GSIS in islets
isolated from NE-infused fetuses was 1.6-fold greater (P<0.05) than controls, but islet insulin
content and intracellular calcium signaling were not different between treatments. The halfmaximal inhibitory concentration for NE was 2.6-fold greater (P<0.05) in NE-infused islets
compared to controls. These findings show that chronic NE exposure and not hyperglycemia
produce persistent adaptations in pancreatic islets that augment β-cell responsiveness in part
through decreased adrenergic sensitivity.
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Introduction
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Fetal stress imposed by complications such as ischemic placental disease leads to prolonged
increases in fetal circulating catecholamines (Okamura et al. 1990; Greenough et al. 1990;
Ananth & Vintzileos 2006; Ananth & Friedman 2014). Elevated epinephrine and
norepinephrine (NE) concentrations in the fetus are primary determinants for adaptive
changes in metabolism and reduced growth rates (Apatu & Barnes 1991; Milley 1997;
Bassett & Hanson 1998; Davis et al. 2015). Catecholamines suppress insulin release via α2adrenergic receptors (α2-ARs) on pancreatic β-cells (Sperling et al. 1984; Jackson et al.
2000; Yates et al. 2012a). In an ovine model of placental insufficiency-induced intrauterine
growth restriction (PI-IUGR), glucose-stimulated insulin secretion (GSIS) was attenuated, in
part, by elevated catecholamine concentrations (Limesand et al. 2006; Macko et al. 2016).
Pharmacological adrenergic blockade in IUGR sheep fetuses ameliorated the deficiency in
GSIS, even though β-cell mass was substantially lower (Leos et al. 2010; Macko et al. 2013;
Limesand et al. 2013). To define the islet response to chronic adrenergic stimulation during
gestation, we infused NE into normal sheep fetuses for seven days and showed that
continuous exposure to high NE concentrations suppressed fetal insulin secretion and raised
fetal glucose concentrations. Moreover, three hours after terminating the chronic NE
infusion, we observed an enhancement in insulin secretion responsiveness to glucose and
arginine challenges (Chen et al. 2014). Expression levels of α2-AR and Gαi-2 protein were
also reduced in islets from this cohort of NE fetuses (Chen et al. 2014). Our findings from
these two distinct models of chronic hypercatecholaminemia, PI-IUGR and NE infusion,
indicate that sustained adrenergic stimulation produces a compensatory augmentation in βcell responsiveness. Therefore, we propose that NE-induced adaptations in fetal islets may
produce a discord between insulin secretion and insulin action during the transition from
fetal to postnatal life, and predispose offspring to metabolic complications.
In this study we test the hypothesis that the compensatory increase in insulin secretion
responsiveness and adrenergic receptor desensitization in islets persist in sheep fetuses after
a period of chronic hypercatecholaminemia and are not dependent upon fetal hyperglycemia.
In our previous work, glucose concentrations were incongruent between IUGR and NEinfused fetuses and both hypo- and hyperglycemia negatively affect β-cell responsiveness
(Carver et al. 1995; Green et al. 2012; Chen et al. 2014; Macko et al. 2016). To avoid
confounding results from glucose, we maintained euglycemic conditions in the fetus during
the NE infusion with a simultaneous maternal infusion of insulin. We show that the
compensatory increase in insulin secretion responsiveness to glucose and arginine
stimulation was present five days after discontinuing the NE treatment. Furthermore,
isolated islets from the NE fetuses exhibited greater GSIS and NE desensitization.

Author Manuscript

Materials and Methods
Animal preparation
Studies were conducted in 15 pregnant Columbia-Rambouillet crossbred ewes carrying a
singleton fetus (Nebeker Ranch, Lancaster, CA). Ewes were fed Standard-Bread Alfalfa
Pellets (Sacate Pellet Mills, AZ) and provided water and salt ad libitum. Indwelling vascular
catheters were surgically placed into ewes and fetuses for arterial blood sampling and
J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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intravenous infusions at 123 ± 1 days gestational age (dGA). Animal husbandry was
performed as previously reported (Chen et al. 2014; Macko et al. 2016). All animal
procedures were approved by the Institutional Animal Care and Use Committee and
performed at the University of Arizona, which is accredited by the American Association for
Accreditation of Laboratory Animal Care.
Experimental treatments

Author Manuscript

Sheep fetuses were randomly assigned to control (n = 7) or NE (n = 8) groups at 129 ± 1
dGA. Control fetuses received an infusion of diluent (0.3% ascorbic acid in 0.9% saline),
and ewes received an infusion of diluent (0.9% saline with 0.5% BSA). NE fetuses received
an infusion of NE (Norepinephrine Bitartrate, Bedford Laboratories, OH; 1–4 μg/min; IV)
for 7 days at preset rates for each day of treatment (day 1 at 1 μg/min, days 2–4 at 2 μg/min,
and days 5–7 at 4μg/min; (Chen et al. 2014)). Insulin (Humulin R; Eli Lilly, Indianapolis,
IN; 30–60 pmol/min/kg) was intravenously infused into ewes to maintain euglycemic
conditions in fetuses during NE infusion (Limesand & Hay, Jr. 2003; Rozance et al. 2006).
The rates of NE infusion were previously shown to recapitulate physiological concentrations
observed in response to fetal hypoxemia in human and sheep (Greenough et al. 1990; Yates
et al. 2012a; Chen et al. 2014). All infusions were terminated on day 7 of treatment, 24
hours prior to the second GSIS study.
Experimental design and insulin secretion studies
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Three GSIS studies were performed before (GSIS-pre), 1 day after (GSIS-1d), and 5 days
after (GSIS-5d) the chronic infusion in all but one control fetus, where the final GSIS study
was lost due to loss of catheter patency. The GSIS studies were conducted as described
previously (Limesand et al. 2006; Leos et al. 2010). Briefly, a continuous transfusion of
maternal arterial blood into the fetus (10 mL/h) was started 30 min prior to sampling and
maintained for the duration of the study to compensate for blood collection. Three baseline
blood samples were collected within the 20 minutes preceding the dextrose bolus at 5–7
minute intervals. The square-wave hyperglycemic clamp was initiated with a dextrose bolus
of 1.19 ± 0.04 mmol/kg estimated fetal weight followed by a constant infusion of 33%
dextrose to increase and maintain fetal arterial plasma glucose concentration at 2.5
± 0.1mmol/L, which produces a near-maximal GSIS response (Green et al. 2011). During
the hyperglycemic clamp, three fetal arterial plasma samples were collected at 45, 50, and
55 min during steady state conditions when concentrations varied less than ± 6% of the
mean and showed no systematic trend with time. Averages for baseline and hyperglycemia
steady state periods were calculated for comparisons. Maximal insulin secretion
responsiveness was measured with a follow-on arginine bolus (0.5 mmol/kg estimated fetal
weight) as described previously (Gresores et al. 1997; Green et al. 2012).
Biochemical analysis
Fetal arterial blood samples were collected and prepared for analysis as described previously
(Chen et al. 2014). Fetal blood samples were collected for blood gasses, pH, and oximetry
measurements with an ABL 725, (temperature-corrected to 39.1°C; Radiometer,
Copenhagen, Denmark). Plasma glucose and lactate concentrations were measured
immediately with a YSI model 2700 SELECT Biochemistry Analyzer (Yellow Springs
J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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Instruments, Yellow Springs, OH). Plasma samples for insulin and NE measurements were
stored at −80°C. Insulin concentrations were measured with an ovine insulin ELISA
(ALPCO Diagnostics, Windham, NH) that had a 9.1% inter-assay and 8.5% intra-assay
coefficients of variation. NE concentrations were measured by Noradrenaline ELISA (Labor
Diagnostika Nord GmbH & Co.KG, Nordhorn, Germany) that had a 22.5% inter-assay and
19.6% intra-assay coefficients of variation.
Necropsy and islet isolation
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After GSIS-5d, animals were recovered for 3–5 hours before ewes and fetuses were
euthanized with an overdose of sodium pentobarbital (86 mg/kg) and phenytoin sodium (11
mg/kg, Euthasol; Virbac Animal Health, Fort Worth, TX). Fetuses and fetal organs were
dissected and weighed. The hepatic portion of pancreas was collected for islet isolation
(Limesand et al. 2006). The splenic portion of pancreas was fixed in 4% paraformaldehyde
overnight and prepared for histological analysis as described previously (Cole et al. 2009).
Islets were isolated after the fetal pancreas was digested in Krebs-Ringer Buffer (KRB) with
Collagenase V (0.425 mg/mL; Sigma) and DNase I (2 μU/mL; Roche Diagnostics,
Mannheim, Germany) as described previously (Limesand et al. 2006; Chen et al. 2014;
Rozance et al. 2015). Isolated islets were washed in KRB containing 0.5% BSA (KRBBSA). Islets were cultured overnight in RPMI-1640 medium (Sigma-Aldrich) supplemented
with 2% fetal bovine serum, 2.8 mmol/L glucose, and penicillin–streptomycin (50 U and 50
mg; Sigma-Aldrich) at 37°C with 95% O2-5% CO2 (Limesand et al. 2006; Green et al.
2012).
Islet static incubations
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Fetal islets from control (n = 6) and NE fetuses (n = 6) were washed twice in KRB-BSA and
a third time in KRB-BSA supplemented with 10 μmol/L forskolin (Sigma-Aldrich). All
media was equilibrated to 37°C and gassed with 95% O2-5% CO2. Ten islets were
handpicked (3–4 replicates/condition for each fetus) and incubated at 37°C in 1 mL KRBBSA-forskolin media with high (11.1 mmol/L) and no (0 mmol/L) glucose, high glucose
plus NE (0.1 nmol/L – 10 μmol/L), and 1.1 mmo/L glucose plus 30 mmol/L KCl. After a 1hour static incubation, islets were pelleted by centrifugation (800 x g) at 4°C for 3 min. The
media was removed and insulin was extracted from islets with acid-ethanol (1 M HCl in
70% ethanol) to determine the islet insulin content. The effectiveness of NE in inhibiting
insulin secretion was determined by the half-maximal inhibitory concentration (IC50) using
the dose response equation (log (inhibitor) vs. normalized response; Prism 6, GraphPad
Software, La Jolla, CA).

Author Manuscript

Whole-islet calcium dynamics
Islets were incubated overnight on glass coverslips pre-coated with human fibronectin (10
mg/L in PBS; BD Biosciences, Bedford, MA, USA; (Green et al. 2011)). Islets from control
and NE fetuses (n = 3/treatment) were washed at 4°C for 10 min with glucose-free Hank’s
Balanced Salt Solution (HBSS; 5 mmol/L KCl, 0.3mmol/L KH2PO4, 138 mmol/L NaCl,
0.2mmol/L NaHCO3, 0.3mmol/L Na2HPO4, 20 mmol/L HEPES, 1.3 mmol/L CaCl2 and
0.4mmol/L MgSO4, pH 7.4) and then loaded with fura-2 acetoxymethylester (2.5 μmol/L;
J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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Molecular Probes) in glucose-free HBSS with 0.0025% pluronic acid for 20 min at 4°C and
20 min at 25°C. The islets were rinsed, incubated in HBSS with 1.1 mmol/L glucose for 10
min at 37°C, and mounted onto the stage of an Olympus IX-70 microscope. Fura-2 was
alternately excited at 340 and 380 nm and emitted light (508 nm) captured on a Photometrics
CH-250 camera as described previously (Lynch et al. 2008). Images were acquired at 0.5–1
minute intervals in the following series of media conditions: low glucose (1.1 mmol/L) for 5
min; high glucose (11.1 mmol/L) for 20 min; 30 mmol/L KCl for 5 min; and 10 μmol/L
ionomycin for 4 min. Data were analyzed for 25–67 fields of view obtained from 2–6 islets
per fetus (coefficient of variation between islets = 6.1%).
Histology of fetal pancreatic endocrine cells
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Pancreatic tissue sections (6 μm) were cut from frozen OCT-embedded control (n = 7) and
NE (n = 6) fetuses and prepared for histological evaluation as described previously (Cole et
al. 2009; Leos et al. 2010). Endocrine cells were identified with guinea pig anti-porcine
insulin (1:500; Dako, Carpinteria, CA), mouse anti-porcine glucagon (1:500; SigmaAldrich), rabbit anti-human somatostatin (1:500; Dako), and rabbit anti-human pancreatic
polypeptide (1:500; Dako). Immunocomplexes were detected with affinity-purified
secondary antiserum conjugated to Cy2 (rabbit), Texas Red (mouse), or 7-amino-4methylcoumarin-3-acetic acid (AMCA, guinea pig; Jackson ImmunoResearch Laboratories,
West Grove, PA) diluted 1:500 in PBS with 1% BSA. Fluorescent staining was visualized on
a Leica DM5500 microscope system and digitally captured with a Spot Pursuit 4 Megapixel
CCD camera (Diagnostic Instruments, Sterling Heights, MI). Morphometric analysis was
performed with ImagePro 6.0 software (Media Cybernetics, Silver Spring, MD). Positive
areas were determined from 25 fields of view (FOV = 0.39 mm2) on two pancreas sections
per animal separated by ≥ 120μm intervals (total area = 19.5 mm2; coefficient of variation
between sections = 10.7%).

Author Manuscript

Statistical analysis
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Differences between treatments (control and NE) for animal weights, daily intake, islet IC50,
and pancreas morphology were analyzed by one-way ANOVA (treatments) using the general
linear means procedure (SAS 9.4, SAS Institute Inc., Cary, NC) and differences were
determined with Student’s t test. Repeated measurement for biochemical, hematological, and
hormone from daily samples, GSIS studies, GPAIS studies, and ex vivo islet experiments
were analyzed by ANOVA using Proc MIXED with fetus as the random effect (SAS 9.4).
Main effects within GSIS studies were treatment, period, and their interaction. Main effects
for GPAIS within treatment were study, sample time, and their interaction. When the overall
ANOVA was significant (α = 0.05), individual means were separated with a least significant
difference test. Data are presented as the mean ± standard error mean.

Results
Animal weights and daily intake
Maternal body weights were not different between control (56.8 ± 3.9 kg) and NE ewes
(52.8 ± 3.3 kg). During the treatment, average daily feed and water intake were similar in
control (1.8 ± 0.1 kg and 7.5 ± 0.9 L) and NE ewes (1.9 ± 0.1 kg and 7.2 ± 0.6 L). Fetal age

J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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at necropsy was similar in control (140 ± 1 dGA, 3 male and 4 female) and NE fetuses (141
± 1 dGA, 7 male and 1 female). Fetal weight was not different between control (3.96 ± 0.23
kg) and NE fetuses (4.02 ± 0.20 kg).
Daily fetal blood parameters
Prior to chronic infusions, fetal plasma glucose, insulin, NE, and blood PaO2 were not
different between experimental groups (Figure 1). During the 7-day infusion, average NE
concentrations were higher (9.26 ± 0.87 ng/mL vs. 0.88 ± 0.11ng/mL, P < 0.01), insulin
concentrations were lower in NE-fetuses compared to controls (0.12 ± 0.01 μg/L vs. 0.43
± 0.02 μg/L, P < 0.01), and glucose concentrations were not different. NE fetuses also had
higher blood PaO2 than controls (27.3 ± 0.5 mmHg vs. 20.8 ± 0.3 mmHg, P < 0.01). There
was no treatment by day interaction for NE, glucose, insulin, or PaO2 during this period.

Author Manuscript

During the 5 days post-infusion, average plasma NE concentrations (2.46 ± 0.41 ng/mL vs.
0.61 ± 0.07 ng/mL; P < 0.01) and blood PaO2 (23.0 ± 0.4 mmHg vs. 20.1 ± 0.4 mmHg, P <
0.01) remained elevated in NE fetuses compared to controls, respectively, but both
measurements were lower (P < 0.05) after infusion than during infusion (Figure 1). Glucose
and insulin concentrations were not different between treatments after the chronic infusion
ended. There was no treatment by day interaction for any of these variables.
Fetal glucose-stimulated insulin secretion

Author Manuscript

By design, glucose concentrations were increased to 2.5 ± 0.1 mmol/L (P < 0.01) from
baseline during the hyperglycemic period of all three GSIS studies (Figure 2). Baseline and
hyperglycemic glucose concentrations were not different between treatments in any GSIS
studies. The glucose infusion rate to maintain the hyperglycemic clamp also was not
different between treatment groups (Table 1).
In the GSIS-pre study, baseline insulin concentrations at either period were not different
between treatments and increased (P < 0.001) with hyperglycemia similarly in both
treatment groups (Figure 2). Baseline insulin concentrations also were not different between
NE and control fetuses in GSIS-1d or GSIS-5d studies, but insulin concentrations during the
hyperglycemic periods were greater (P < 0.05) in NE fetuses than controls in both studies.
Insulin secretion responsiveness (difference between baseline and hyperglycemic insulin
concentrations) was not different among three GSIS studies in control fetuses. In NE fetuses,
however, insulin secretion responsiveness was greater (P < 0.01) in GSIS-1d (1.46 ± 0.36
μg/L) and GSIS-5d (1.77 ± 0.44 μg/L) compared to GSIS-pre (0.66 ± 0.12 μg/L).
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Blood gas, pH, hematocrit, plasma lactate, and plasma NE were not different between
treatments in GSIS-pre, although differences in period means were found; there was no
treatment by period interaction (Table 1). In GSIS-1d, NE fetuses had greater PaO2 (25.4
± 0.5 mmHg vs. 20.0 ± 0.3 mmHg, P < 0.01), blood oxygen content (4.0 ± 0.1 mmol/L vs.
3.1 ± 0.1 mmol/L, P < 0.05) and NE concentrations (3.33 ± 0.42 ng/mL vs. 0.61 ± 0.05
ng/mL, P < 0.01) than controls, respectively. The blood PaCO2 values were lower in NE
fetuses than controls (46.7 ± 0.5 mmHg vs. 51.0 ± 0.3 mmHg, P < 0.01), while pH,
hematocrit, and lactate were not different. In GSIS-5d NE remained greater than controls
(1.54 ± 0.14 ng/mL vs. 0.62 ± 0.07 ng/mL, P < 0.05; Table 1).
J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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GPAIS was enhanced in NE fetuses following infusion but controls were unaffected (Figure
3). Average GPAIS insulin concentrations in NE fetuses were greater (P < 0.01) in
GPAIS-1d (4.02 ± 0.39 μg/L) and GPAIS-5d (3.64 ± 0.35 μg/L) compared to GPIAS-pre
(2.66 ± 0.19 μg/L), which was similar to all three control GPAIS studies.
Islet responsiveness
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Insulin secretion rates from isolated fetal sheep islets were measured in the presence of 11.1
mmol/L glucose and various NE concentrations (Figure 4A). Maximum glucose-stimulated
insulin secretion was greater in NE islets than control islets (2.20 ± 0.27 ng/islet/h vs. 1.38
± 0.24 ng/islet/h, P < 0.05). Minimum insulin secretion rates with NE inhibition were not
different between NE (0.74 ± 0.18 ng/islet/h) and control islets (0.68 ± 0.15 ng/islet/h), and
these rates were also not different from incubations with no glucose. In islet incubations
with 30 mmol/L KCl, insulin secretion rates were greater (P < 0.05) than other conditions
but not different between treatments (NE, 8.84 ± 1.47 ng/islet/h vs. control, 5.66 ± 1.91 ng/
islet/h). The IC50 concentration was greater (P < 0.05) for NE than control islets (Figure
4B). Insulin contents of isolated islets were not different between NE and control fetuses
(Figure 4C).
Cytosolic calcium concentrations at 1.1 mmol/L glucose were not different between NE and
control islets (340/380 ratio of 0.66 ± 0.01 in NE and 0.67 ± 0.06 in controls). High glucose
concentrations and 30 mmol/L KCl increased intracellular calcium, but means were not
different between treatments (0.71 ± 0.01 in NE vs. 0.73 ± 0.07 in control for high glucose,
and 1.24 ± 0.08 in NE vs. 1.46 ± 0.20 in control for KCl).
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Pancreatic endocrine cell area
There were no differences in the total area staining positive for insulin (β-cells), glucagon
(α-cells), or the combination of somatostatin (δ-cells) and pancreatic polypeptide cells (Fcells) between treatments (Table 2).

Discussion

Author Manuscript

Fetal stress associated with placental dysfunction chronically elevates catecholamines
(Okamura et al. 1990; Greenough et al. 1990). In this study, we demonstrate that sustained
exposure to elevated NE directly produces lasting adaptations in fetal β-cells. The
compensatory increase in insulin secretion responsiveness to glucose and arginine was still
observed five days after cessation of the NE infusion. Furthermore, we confirmed enhanced
insulin secretion to glucose was intrinsic to the islets following isolation. Although the
increased β-cell responsiveness to glucose and arginine was not explained by differences in
β-cell mass, insulin content, or intracellular calcium signaling, the β-cells remained
desensitized to adrenergic stimulation, which supports previous findings that show lower
expression of adrenergic receptors and signaling molecules (Chen et al. 2014). Previously,
IUGR fetuses with elevated catecholamines exhibited improved β-cell responsiveness during
adrenergic blockade, indicating adaptive programming effects from chronic adrenergic
stimulation are present (Leos et al. 2010; Macko et al. 2013). In these previous studies, we

J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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found the compensatory increase in insulin secretion responsiveness immediately after
reducing the adrenergic stimulation, whereas here we show the enhancement was maintained
for five days following removal of elevated adrenergic stimulation indicating that the effects
were programmed.
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Enhanced insulin secretion responsiveness to secretagogues and adrenergic desensitization
represent two functional adaptations in the β-cell that persisted well beyond the end of NE
infusion. These findings expand our previous work where we observed a compensatory
increase in insulin secretion three hours after terminating the NE infusion and also showed
lower expression of α2-ARs and Gαi-2 protein in fetal sheep islets. It is likely that these two
effects are interrelated because recent genetic studies reveal that overexpression of α2A-AR
causes impaired docking and exocytosis of insulin granules (Rosengren et al. 2010;
Rosengren et al. 2012; Straub & Sharp 2012). However, this tonic inhibition of insulin
release was alleviated with α2-AR antagonists (Rosengren et al. 2010; Yang et al. 2012).
Conversely, α2A-AR deficient mice not only lack inhibitory actions in pancreatic β-cell but
also are hyperinsulinemic and hypoglycemic (Fagerholm et al. 2004; Savontaus et al. 2008).
The α2-ARs desensitization in pancreatic β-cells found in the present study may, in part,
explain the compensatory increase in β-cell responsiveness following cessation of
hypercatecholaminemia because of the loss of tonic inhibition by adrenergic receptors.

Author Manuscript
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Alternative mechanisms for enhanced GSIS and GPAIS responsiveness in the NE fetus may
include increased metabolic coupling to oxidative phosphorylation or regulation of secretory
granule exocytosis. We have previously shown that uncoupling protein 2 (UCP2) mRNA
expression is reduced in NE islets following acute recovery overnight culture in vivo (Chen
et al. 2014). In β-cells, UCP2 is a negative regulator of insulin secretion because it decreases
the proton-motive force in the inner mitochondria membrane to circumvent ATP synthesis
(Zhang et al. 2001; Affourtit & Brand 2006; Affourtit & Brand 2008). Conversely, a
reduction of UCP2 as identified in islets of NE fetuses enhances insulin secretion (Zhang et
al. 2006; Robson-Doucette et al. 2011). The reduction in UCP2 expression in NE islets may
be a direct effect of adrenergic stimulation or an indirect effect because adrenergic
stimulation decrease rates of glucose metabolism (Laychock & Bilgin 1987; Laychock 1989;
Dalgaard 2012). Transcriptome expression analysis by high-throughput RNA sequencing of
NE islets revealed significant increases in chloride channel, calcium activated, family
member 1 (CLCA1) and FXYD domain containing ion transport regulator 2 and significant
decreases in solute carrier family 9 member A2 (Na+/H+ Exchanger 2) and inositol 1,4,5trisphosphate receptor type 2 in NE islets compared to controls after the acute recovery
(unpublished data). Although additional work is necessary to determine the role of these ion
channels in the NE islets, there is evidence that chloride flux across the β-cell membrane can
modulate exocytotic capacity and alter depolarization kinetics (Barg et al. 1999; Barg et al.
2001; Thevenod 2002).
In our previous study using chronic 7-day NE infusion, we observed hyperglycemia and
increased arterial blood oxygen tension in NE fetuses during the treatment. In the present
study, we maintained fetal glucose concentrations at normal values to eliminate the
confounding influence of chronic hyperglycemia, which was previously demonstrated to
negatively influence insulin secretion (Carver et al. 1995; Green et al. 2012). Here, we
J Endocrinol. Author manuscript; available in PMC 2018 February 01.
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confirm that the NE-induced compensation in fetal sheep islets is independent of the fetal
glucose concentrations. Moreover, when we compare the NE fetal cohorts and the PI-IUGR
fetal sheep cohort that is hypoglycemic (Leos et al. 2010; Macko et al. 2013), we can
exclude an influence of fetal glucose concentrations for the compensatory enhancement in
β-cell function following chronic NE exposure because it is present in fetuses with hypo-,
hyper-, and euglycemic conditions. Similarly, oxygen tension is not expected to affect these
results because they persist in models with different fetal oxygenation. Acutely, in normal
sheep fetuses, higher blood PaO2 did not augment GSIS (Jackson et al. 2000), and when
placental insufficiency-induced IUGR fetuses were oxygenated to normal levels from
hypoxemia, insulin secretion was enhanced independently of norepinephrine concentrations
(Macko et al. 2016).
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Plasma NE concentrations of NE fetuses remained 5.3-fold and 2.5-fold higher than controls
at one and five days after terminating NE infusion, respectively. Chronic NE exposure or
physiological hypoxic challenges in fetal sheep and lambs inhibit catecholamine clearance
rates in the placenta and lung, which partially explain the prolonged elevation (Chappell et
al. 1991; Bzoskie et al. 1995; Bzoskie et al. 1997). Also, if α2-ARs on the adrenal
chromaffin cells were desensitized increased rates of NE synthesis would be expected,
because the adrenal glands possess short feedback inhibition similar to sympathetic neurons
(Brede et al. 2003; Moura et al. 2006). Despite the elevation of NE, NE fetuses still had
significantly higher β-cell responsiveness, indicating that the new levels of catecholamines
are below effective concentrations to inhibit insulin secretion.
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Persistence in enhanced insulin secretion responsiveness resulting from chronically elevated
NE in utero begins to explain the common occurrence for transient hyperinsulinemic
hypoglycemia seen in infants born small for gestational age or with perinatal stress (Collins
et al. 1990; Duvanel et al. 1999; Stanley et al. 2015). The baseline insulin and glucose
concentrations in NE fetuses are equivalent to controls, but glucose concentrations will
increase after delivery. If the increased β-cell sensitivity continues postnatally, it is
anticipated that hyperinsulinemia will pursue and lower neonatal glucose concentrations.
Hyperinsulinemia and hypoglycemia will be exacerbated by adrenergic receptor
desensitization because counter regulatory mechanisms for glucose homeostasis will be
reduced (Hawdon et al. 1993; Rozance & Hay, Jr. 2010; Chen et al. 2010). Although
management of asymptomatic hypoglycemia is controversial, reoccurring episodes are
associated with poor neurodevelopment and growth deficits (Duvanel et al. 1999; Rozance &
Hay, Jr. 2016). Therefore, while the symptoms may resolve, there are potential long term
consequences to transient hyperinsulinemic hypoglycemia in neonate that may result from
chronically elevated NE.

Author Manuscript

In conclusion, chronic elevation of NE concentration, not hyperglycemia, produces a
compensatory enhancement in β-cell responsiveness to insulin secretagogues after
terminating the NE infusion in fetal sheep. Improved insulin secretion was intrinsic to
pancreatic islets, which maintained α2-AR desensitization six days after termination of NE
infusion, which may contribute to the manifestation of persistent adaptation in β-cells.
Although previous studies in PI-IUGR fetuses and lambs support peripheral adrenergic
receptor desensitization that impairs the ability of catecholamines to mobilize free fatty
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acids (Chen et al. 2010; Yates et al. 2012b; Yates et al. 2016), this is the first study to
describe programming effects from NE in β-cells. Importantly, the β-cell dysfunction
created by NE-infusion begins to explain the potential variability in small-for-gestational age
infants because sustained exposure to high catecholamine levels is found in IUGR infants.
The enhanced β-cell responsiveness induced by chronic high catecholamine concentrations
in the fetus will create an imbalance in the insulin disposition index that may impair the
maturation of glucose homeostasis.
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Figure 1. NE Infusion Inhibits Insulin Concentrations
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Daily arterial means are presented for control (circles, n = 7) and NE fetuses (squares, n =
8). Values for plasma norepinephrine (A), plasma glucose (B), plasma insulin (C) and partial
pressure of blood oxygen (PaO2, D) were determined for each day of treatment (x-axis).
Difference (P < 0.05) during the infusion and post-infusion periods are identified with an
asterisk.
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Figure 2. Persistent Enhancement of GSIS in NE fetuses

Author Manuscript

Plasma glucose and insulin concentrations are presented for the three GSIS studies, which
are labeled above the graphs: before (GSIS-pre), 1 day after (GSIS-1d) and 5 days after
(GSIS-5d) the chronic infusion. Baseline and hyperglycemic steady state period means for
control (n = 6–7) and NE fetuses (n = 8) were analyzed within each GSIS study. Differences
(P < 0.05) between control and NE fetuses within the period are identified (*).
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Figure 3. Persistent Enhancement of GPAIS in NE Fetuses
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Insulin concentrations are presented for the GPAIS studies in control (A, n = 6–7) and NE
fetuses (B, n = 8). The arginine bolus is administered at time 0. GPAIS studies were
conducted before (GPAIS-pre), 1 day after (GPAIS-1d) and 5 days after (GPAIS-5d) the
chronic treatment. There was no study by time interaction. Study differences (*; P < 0.05)
for the average insulin concentration were observed in the NE fetuses but not controls.
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Figure 4. Enhanced Glucose Stimulated Insulin Secretion in NE Islets
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Pancreatic islets were isolated from control and NE fetuses (n = 6 animals/treatment). A)
Insulin secretion rates were measured in static incubations that contain 11.1 mmol/L glucose
and various NE concentrations that ranged from 0–10 μmol/L (y-axis). The bar with
asterisks indicate that the maximum insulin secretion rate was significantly different (P <
0.01) between control and NE islets. B) The half maximal inhibitory concentration (IC50)
was calculated for each treatment. Values represent means ± SEM, and the asterisks
indicates a difference (P < 0.05) between treatment groups. C) Islet insulin contents were not
different between treatments.
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GSIS-1d

7.31 ± 0.01

J Endocrinol. Author manuscript; available in PMC 2018 February 01.

Lactate (mmol/L)

Hematocrit (%)

Oxygen Content (mmol/L)

PaCO2 (mmHg)

2.12 ± 0.13
2.66 ± 0.13

Hyperglycemia

33.5 ± 0.8

Baseline

34.0 ± 1.0

Hyperglycemia

3.0 ± 0.1

Baseline

3.2 ± 0.2

Hyperglycemia

51.4 ± 0.5

Baseline

50.5 ± 0.4

Hyperglycemia

19.9 ± 0.5

Hyperglycemia
Baseline

20.1 ± 0.5

Baseline

7.30 ± 0.01

Hyperglycemia

PaO2 (mmHg)

7.32 ± 0.01

Baseline

pH

14.2 ± 0.9

0.61 ± 0.10

Hyperglycemia
Hyperglycemia

0.50 ± 0.08

2.50 ± 0.09

Baseline

Hyperglycemia

32.9 ± 0.6
2.03 ± 0.09

Baseline

Hyperglycemia

3.3 ± 0.1
33.3 ± 0.6

Hyperglycemia
Baseline

3.7 ± 0.1

50.3 ± 0.6

Hyperglycemia
Baseline

48.8 ± 0.5

20.5 ± 0.3

Baseline

Hyperglycemia

21.3 ± 0.3

Glucose Infusion (mmol/hr)

NE (ng/mL)

Lactate (mmol/L)

Hematocrit (%)

Oxygen Content (mmol/L)

PaCO2 (mmHg)

Baseline

Hyperglycemia

PaO2 (mmHg)

Baseline

pH

11.0 ± 1.2
7.33 ± 0.01

Hyperglycemia

Glucose Infusion (mmol/hr)

Control (n = 7)

GSIS-pre

Period

Parameter

Study

1.78 ± 0.09

1.33 ± 0.07

31.8 ± 0.5

32.3 ± 0.4

3.8 ± 0.1

4.2 ± 0.1

47.2 ± 0.7

46.1 ± 0.6

24.7 ± 0.8

26.0 ± 0.6

7.30 ± 0.01

7.32 ± 0.01

11.8 ± 1.1

0.72 ± 0.13

0.53 ± 0.08

2.33 ± 0.08

1.94 ± 0.08

34.3 ± 0.3

34.6 ± 0.4

3.5 ± 0.1

3.7 ± 0.1

50.7 ± 0.5

49.4 ± 0.4

20.9 ± 0.5

20.9 ± 0.6

7.32 ± 0.01

7.34 ± 0.01

12.5 ± 0.7

NE (n = 8)

< 0.01

NS

< 0.05

< 0.01

< 0.01

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

P-value Treatment

< 0.01

< 0.01

< 0.01

< 0.01

< 0.05

< 0.01

< 0.05

< 0.01

< 0.01

< 0.05

< 0.01

< 0.05

< 0.01

P-value Period

Glucose infusion, blood gas, lactate, and norepinephrine concentrations during GSIS studies.
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NE (pg/mL)

Lactate (mmol/L)

Hematocrit (%)

Oxygen Content (mmol/L)

PaCO2 (mmHg)

0.56 ± 0.11
0.67 ± 0.09

Hyperglycemia

3.11 ± 0.20

Baseline

Hyperglycemia

30.9 ± 0.9
2.37 ± 0.15

Baseline

Hyperglycemia

2.5 ± 0.1
31.3 ± 1.0

Hyperglycemia
Baseline

2.8 ± 0.1

51.6 ± 0.6

Hyperglycemia
Baseline

50.7 ± 0.5

19.3 ± 0.5

Hyperglycemia
Baseline

20.3 ± 0.6

7.30 ± 0.01

Baseline

Hyperglycemia
PaO2 (mmHg)

Baseline

pH

14.3 ± 1.1
7.32 ± 0.01

Hyperglycemia

Glucose Infusion (mmol/hr)

0.62 ± 0.07

Hyperglycemia

NS, not significant.

Values are means ± SEM.

No significant interactions between treatment and period were identified.

GSIS-5d

0.59 ± 0.06

Baseline

NE (ng/mL)

Control (n = 7)

Period

Author Manuscript
Parameter

1.50 ± 0.23

1.60 ± 0.17

2.66 ± 0.10

2.04 ± 0.13

30.5 ± 0.6

30.9 ± 0.6

2.9 ± 0.1

3.1 ± 0.1

52.7 ± 0.4

51.4 ± 0.3

20.3 ± 0.5

20.7 ± 0.4

7.31 ±0.01

7.34 ± 0.01

13.7 ± 0.8

3.55 ± 0.65

3.11 ± 0.56

NE (n = 8)

< 0.05

NS

NS

NS

NS

NS

NS

NS

< 0.01

P-value Treatment

NS

< 0.01

< 0.01

< 0.01

< 0.01

< 0.05

< 0.01

NS

P-value Period

Author Manuscript

Study

Chen et al.
Page 19

Author Manuscript

J Endocrinol. Author manuscript; available in PMC 2018 February 01.

Chen et al.

Page 20

Table 2

Author Manuscript

Endocrine pancreas morphometry.
Control (n = 7)

NE (n = 6)

β-cell area, %

2.22±0.43

2.04±0.26

α-cell area, %

1.48±0.19

1.67±0.28

δ- and PP-cell area, %

0.97±0.10

0.98±0.17

Total Endocrine Area, %

4.66 ± 0.67

4.69 ± 0.61

PP, pancreatic polypeptide.
Values are means ± SEM.
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